首页> Clinical lymphoma, myeloma & leukemia> A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.

A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Julie,Stakiw

第一单位： Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

作者： Julie,Stakiw ^[1] ; Shruthi,Kodad ^[1] ; Richard,LeBlanc ^[2] ; Michael,Sebag ^[3] ; Annette E,Hay ^[4] ; Vishal,Kukreti ^[5] ; Julie,Côté ^[6] ; Fernando,Camacho ^[7] ; Molei,Fu ^[7] ; Engin,Gul ^[7] ; Donna,Reece ^[8]

作者单位： Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. ^[1] Maisonneuve-Rosemont Hospital Research Centre, University of Montréal, Montréal, Quebec, Canada. ^[2] Department of Oncology, Division of Hematology, McGill University, Montréal, Quebec, Canada. ^[3] Department of Medicine, Queen's University, Kingston, Ontario, Canada. ^[4] Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. ^[5] Hôpital de l'Enfant-Jésus, CHU de Québec, Université Laval, Québec, Quebec, Canada. ^[6] CMRG is an independent non-profit CRO (clinical research organization), Canadian Myeloma Research Group, Vaughan, Ontario, Canada. ^[7] CMRG is an independent non-profit CRO (clinical research organization), Canadian Myeloma Research Group, Vaughan, Ontario, Canada. Electronic address: donna.reece@uhn.ca. ^[8]

关键词 Anti-CD38 monoclonal antibody Infusion reactions Rapid infusion Refractory myeloma

医学主题词人类(Humans);抗体, 单克隆(Antibodies, Monoclonal);多发性骨髓瘤(Multiple Myeloma);疾病大流行(Pandemics);前瞻性研究(Prospective Studies);回顾性研究(Retrospective Studies)

DOI 10.1016/j.clml.2023.03.006

PMID 37127473

发布时间 2023-06-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交